Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: Promises and challenges

Clinical Biochemistry

Volumn 46, Issue 10-11, 2013, Pages 846-860

  De Guire, V ^a   Robitaille, R ^a   Tetreault N ^a   Guerin R ^b   Menard C ^c   Bambace, N ^a   Sapieha, P ^c  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b CHICOUTIMI HOSPITAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Area under the curve; Blood; Cancer; Clinical; MicroRNA; MiRNA; Pitfalls; Review; Sensitivity; Specificity

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 1; MICRORNA 100; MICRORNA 122; MICRORNA 125B; MICRORNA 126; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 182; MICRORNA 192; MICRORNA 200A; MICRORNA 200B; MICRORNA 210; MICRORNA 214; MICRORNA 22; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 24; MICRORNA 26A; MICRORNA 29A; MICRORNA 31; MICRORNA 34A; MICRORNA 375;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; AMNION FLUID; AREA UNDER THE CURVE; B CELL LYMPHOMA; BLADDER CANCER; BRAIN ISCHEMIA; BREAST CANCER; BREAST MILK; BRONCHUS SECRETION; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CEREBROSPINAL FLUID; CHRONIC HEPATITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL LABORATORY; COLORECTAL CANCER; COLOSTRUM; DIAGNOSTIC ACCURACY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HEART FAILURE; HEPATITIS C; HUMAN; KIDNEY CARCINOMA; LACRIMAL FLUID; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOUTH SQUAMOUS CELL CARCINOMA; MYCOBACTERIUM TUBERCULOSIS; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERITONEAL FLUID; PLEURA FLUID; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PULMONARY VASCULAR DISEASE; REVIEW; RHABDOMYOSARCOMA; SEMINAL PLASMA; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TUBERCULOSIS; UPREGULATION; URINE; VIRUS HEPATITIS;

ANIMALS; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MICRORNAS; MONITORING, PHYSIOLOGIC;

EID: 84886100468     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.03.015     Document Type: Review

References (164)

1. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901-906.
2. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
3. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
4. Selbach M., Schwanhausser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
5. Krek A., Grun D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., et al. Combinatorial microRNA target predictions. Nat Genet 2005, 37:495-500.
6. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
7. Bruneau B.G. Developmental biology: tiny brakes for a growing heart. Nature 2005, 436:181-182.
8. Sylvestre Y., De Guire V., Querido E., Mukhopadhyay U.K., Bourdeau V., Major F., et al. An e2f/mir-20a autoregulatory feedback loop. J Biol Chem 2007, 282:2135-2143.
9. De Guire V., Caron M., Scott N., Menard C., Gaumont-Leclerc M.F., Chartrand P., et al. Designing small multiple-target artificial RNAs. Nucleic Acids Res 2010, 38:e140.
10. Esau C., Kang X., Peralta E., Hanson E., Marcusson E.G., Ravichandran L.V., et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004, 279:52361-52365.
11. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes mir15 and mir16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
12. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. Mir-15 and mir-16 induce apoptosis by targeting bcl2. Proc Natl Acad Sci U S A 2005, 102:13944-13949.
13. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
14. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
15. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
16. Rosenfeld N., Aharonov R., Meiri E., Rosenwald S., Spector Y., Zepeniuk M., et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008, 26:462-469.
17. Anglicheau D., Sharma V.K., Ding R., Hummel A., Snopkowski C., Dadhania D., et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 2009, 106:5330-5335.
18. Wu F., Zhang S., Dassopoulos T., Harris M.L., Bayless T.M., Meltzer S.J., et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis 2010, 16:1729-1738.
19. Ma Y., Zhang P., Yang J., Liu Z., Yang Z., Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer 2012, 130:2077-2087.
20. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large b-cell lymphoma. Br J Haematol 2008, 141:672-675.
21. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
22. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
23. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108:5003-5008.
24. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
25. Thery C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep 2011, 3:15.
26. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
27. Rabinowits G., Gercel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009, 10:42-46.
28. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008, 110:13-21.
29. Hu G., Drescher K.M., Chen X.M. Exosomal miRNAs: biological properties and therapeutic potential. Front Genet 2012, 3:56.
30. Vickers K.C., Remaley A.T. Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol 2012, 23:91-97.
31. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13:423-433.
32. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467-477.
33. Fabbri M., Paone A., Calore F., Galli R., Gaudio E., Santhanam R., et al. MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012, 109:E2110-E2116.
34. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
35. Gilad S., Lithwick-Yanai G., Barshack I., Benjamin S., Krivitsky I., Edmonston T.B., et al. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn 2012, 14:510-517.
36. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
37. Chen X., Hu Z., Wang W., Ba Y., Ma L., Zhang C., et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012, 130:1620-1628.
38. Boeri M., Verri C., Conte D., Roz L., Modena P., Facchinetti F., et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011, 108:3713-3718.
39. Jeong H.C., Kim E.K., Lee J.H., Lee J.M., Yoo H.N., Kim J.K. Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Rep 2011, 4:383-387.
40. Roa W.H., Kim J.O., Razzak R., Du H., Guo L., Singh R., et al. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin Invest Med 2012, 35:E271.
41. Wang Y.Y., Ren T., Cai Y.Y., He X.Y. MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95d by regulating K-Ras and HMGA2 gene expression. Cancer Biother Radiopharm 2012, 2:131-137.
42. Nair V.S., Maeda L.S., Ioannidis J.P. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012, 104:528-540.
43. Dye C., Williams B.G. The population dynamics and control of tuberculosis. Science 2010, 328:856-861.
44. Fu Y., Yi Z., Wu X., Li J., Xu F. Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol 2011, 49:4246-4251.
45. Kapinas K., Kessler C., Ricks T., Gronowicz G., Delany A.M. Mir-29 modulates wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 2010, 285:25221-25231.
46. Xiao J., Jing Z.C., Ellinor P.T., Liang D., Zhang H., Liu Y., et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med 2011, 9:159.
47. Perrier A., Nendaz M.R., Sarasin F.P., Howarth N., Bounameaux H. Cost-effectiveness analysis of diagnostic strategies for suspected pulmonary embolism including helical computed tomography. Am J Respir Crit Care Med 2003, 167:39-44.
48. Brown M.D., Rowe B.H., Reeves M.J., Bermingham J.M., Goldhaber S.Z. The accuracy of the enzyme-linked immunosorbent assay d-dimer test in the diagnosis of pulmonary embolism: a meta-analysis. Ann Emerg Med 2002, 40:133-144.
49. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
50. Ng E.K., Li R., Shin V.Y., Jin H.C., Leung C.P., Ma E.S., et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 2013, 8:e53141.
51. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
52. Heneghan H.M., Miller N., Kelly R., Newell J., Kerin M.J. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010, 15:673-682.
53. Zhao H., Shen J., Medico L., Wang D., Ambrosone C.B., Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010, 5:e13735.
54. Yi Z., Fu Y., Zhao S., Zhang X., Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol 2010, 136:855-862.
55. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol 2007, 17:303-308.
56. Redova M., Poprach A., Nekvindova J., Iliev R., Radova L., Lakomy R., et al. Circulating mir-378 and mir-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012, 10:55.
57. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010, 28:655-661.
58. Scian M.J., Maluf D.G., David K.G., Archer K.J., Suh J.L., Wolen A.R., et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with if/ta. Am J Transplant 2011, 11:2110-2122.
59. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
60. Aravalli R.N., Cressman E.N., Steer C.J. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 2013, 87:227-247.
61. Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., et al. Circulating microRNAs, mir-21, mir-122, and mir-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011, 50:136-142.
62. Zhou J., Yu L., Gao X., Hu J., Wang J., Dai Z., et al. Plasma microRNA panel to diagnose hepatitis b virus-related hepatocellular carcinoma. J Clin Oncol 2011, 29:4781-4788.
63. Zhang Y., Jia Y., Zheng R., Guo Y., Wang Y., Guo H., et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010, 56:1830-1838.
64. Gui J., Tian Y., Wen X., Zhang W., Zhang P., Gao J., et al. Serum microRNA characterization identifies mir-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011, 120:183-193.
65. Li L.M., Hu Z.B., Zhou Z.X., Chen X., Liu F.Y., Zhang J.F., et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010, 70:9798-9807.
66. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
67. Song J.H., Meltzer S.J. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 2012, 143:35-47. [e2].
68. Zhang C., Wang C., Chen X., Yang C., Li K., Wang J., et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010, 56:1871-1879.
69. Zhang T., Wang Q., Zhao D., Cui Y., Cao B., Guo L., et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond) 2011, 121:437-447.
70. Liu C.J., Kao S.Y., Tu H.F., Tsai M.M., Chang K.W., Lin S.C. Increase of microRNA mir-31 level in plasma could be a potential marker of oral cancer. Oral Dis 2010, 16:360-364.
71. Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Morimura R., Nagata H., et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011, 105:104-111.
72. Zhang T., Zhao D., Wang Q., Yu X., Cui Y., Guo L., et al. MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Mol Carcinog 2012, 1-10.
73. Wang F., Sun G.P., Zou Y.F., Hao J.Q., Zhong F., Ren W.J. MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark 2012, 11:259-267.
74. Li Y., Yang Y., Lu M., Shen L. Predictive value of serum cea, ca19-9 and ca72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology 2011, 58:2166-2170.
75. Olive V., Jiang I., He L. Mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010, 42:1348-1354.
76. Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010, 102:1174-1179.
77. Liu R., Zhang C., Hu Z., Li G., Wang C., Yang C., et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011, 47:784-791.
78. Petrocca F., Vecchione A., Croce C.M. Emerging role of mir-106b-25/mir-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 2008, 68:8191-8194.
79. Luo X., Burwinkel B., Tao S., Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol Biomarkers Prev 2011, 20:1272-1286.
80. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
81. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010, 127:118-126.
82. McKenna L.B., Schug J., Vourekas A., McKenna J.B., Bramswig N.C., Friedman J.R., et al. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010, 139:1654-1664. [64 e1].
83. Herszenyi L., Farinati F., Cardin R., Istvan G., Molnar L.D., Hritz I., et al. Tumor marker utility and prognostic relevance of cathepsin b, cathepsin l, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, cea and ca 19-9 in colorectal cancer. BMC Cancer 2008, 8:194.
84. Zahm A.M., Thayu M., Hand N.J., Horner A., Leonard M.B., Friedman J.R. Circulating microRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2011, 53:26-33.
85. Hurst D.R., Edmonds M.D., Welch D.R. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009, 69:7495-7498.
86. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
87. Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008, 18:350-359.
88. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., et al. MicroRNA-21 (mir-21) post-transcriptionally downregulates tumor suppressor pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
89. Lu Z., Liu M., Stribinskis V., Klinge C.M., Ramos K.S., Colburn N.H., et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008, 27:4373-4379.
90. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the pten tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
91. Iorio M.V., Croce C.M. MicroRNA involvement in human cancer. Carcinogenesis 2012, 33:1126-1133.
92. Fu X., Han Y., Wu Y., Zhu X., Lu X., Mao F., et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 2011, 41:1245-1253.
93. Lawrie C.H., Soneji S., Marafioti T., Cooper C.D., Palazzo S., Paterson J.C., et al. MicroRNA expression distinguishes between germinal center b cell-like and activated b cell-like subtypes of diffuse large b cell lymphoma. Int J Cancer 2007, 121:1156-1161.
94. Ai J., Zhang R., Li Y., Pu J., Lu Y., Jiao J., et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010, 391:73-77.
95. Keller A., Leidinger P., Lange J., Borries A., Schroers H., Scheffler M., et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009, 4:e7440.
96. Kong X., Du Y., Wang G., Gao J., Gong Y., Li L., et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: Mir-196a could be a potential marker for poor prognosis. Dig Dis Sci 2011, 56:602-609.
97. Wang F., Wang X.S., Yang G.H., Zhai P.F., Xiao Z., Xia L.Y., et al. Mir-29a and mir-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep 2012, 39:2713-2722.
98. Wu J., Lu C., Diao N., Zhang S., Wang S., Wang F., et al. Analysis of microRNA expression profiling identifies mir-155 and mir-155* as potential diagnostic markers for active tuberculosis: a preliminary study. Hum Immunol 2012, 73:31-37.
99. McDonald J.S., Milosevic D., Reddi H.V., Grebe S.K., Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011, 57:833-840.
100. Wang K., Yuan Y., Cho J.H., McClarty S., Baxter D., Galas D.J. Comparing the microRNA spectrum between serum and plasma. PLoS One 2012, 7:e41561.
101. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
102. Mo M.H., Chen L., Fu Y., Wang W., Fu S.W. Cell-free circulating miRNA biomarkers in cancer. J Cancer 2012, 3:432-448.
103. Duttagupta R., Jiang R., Gollub J., Getts R.C., Jones K.W. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011, 6:e20769.
104. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012, 5:492-497.
105. Accerbi M., Schmidt S.A., De Paoli E., Park S., Jeong D.H., Green P.J. Methods for isolation of total RNA to recover miRNAs and other small RNAs from diverse species. Methods Mol Biol 2010, 592:31-50.
106. Ach R.A., Wang H., Curry B. Measuring microRNAs: comparisons of microarray and quantitative pcr measurements, and of different total RNA prep methods. BMC Biotechnol 2008, 8:69.
107. Kim Y.K., Yeo J., Kim B., Ha M., Kim V.N. Short structured RNAs with low gc content are selectively lost during extraction from a small number of cells. Mol Cell 2012, 46:893-895.
108. Baker M. MicroRNA profiling: separating signal from noise. Nat Methods 2010, 7:687-692.
109. Pritchard C.C., Cheng H.H., Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012, 13:358-369.
110. Git A., Dvinge H., Salmon-Divon M., Osborne M., Kutter C., Hadfield J., et al. Systematic comparison of microarray profiling, real-time pcr, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010, 16:991-1006.
111. Chugh P., Dittmer D.P. Potential pitfalls in microRNA profiling. Wiley Interdiscip Rev RNA 2012, 3:601-616.
112. Hafner M., Renwick N., Brown M., Mihailovic A., Holoch D., Lin C., et al. Rna-ligase-dependent biases in miRNA representation in deep-sequenced small RNA cDNA libraries. RNA 2011, 17:1697-1712.
113. Nelson P.T., Wang W.X., Wilfred B.R., Tang G. Technical variables in high-throughput miRNA expression profiling: much work remains to be done. Biochim Biophys Acta 2008, 1779:758-765.
114. Castoldi M., Benes V., Hentze M.W., Muckenthaler M.U. Michip: a microarray platform for expression profiling of microRNAs based on locked nucleic acid (lna) oligonucleotide capture probes. Methods 2007, 43:146-152.
115. Roush S., Slack F.J. The let-7 family of microRNAs. Trends Cell Biol 2008, 18:505-516.
116. Jensen S.G., Lamy P., Rasmussen M.H., Ostenfeld M.S., Dyrskjot L., Orntoft T.F., et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 2011, 12:435.
117. Lee L.W., Zhang S., Etheridge A., Ma L., Martin D., Galas D., et al. Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 2010, 16:2170-2180.
118. Ebhardt H.A., Fedynak A., Fahlman R.P. Naturally occurring variations in sequence length creates microRNA isoforms that differ in argonaute effector complex specificity. Silence 2010, 1:12.
119. Kuchenbauer F., Morin R.D., Argiropoulos B., Petriv O.I., Griffith M., Heuser M., et al. In-depth characterization of the microRNA transcriptome in a leukemia progression model. Genome Res 2008, 18:1787-1797.
120. Meyer S.U., Pfaffl M.W., Ulbrich S.E. Normalization strategies for microRNA profiling experiments: a 'normal' way to a hidden layer of complexity?. Biotechnol Lett 2010, 32:1777-1788.
121. Benes V., Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 2010, 50:244-249.
122. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33:e179.
123. Gidlof O., Andersson P., van der Pals J., Gotberg M., Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011, 118:217-226.
124. de Planell-Saguer M., Rodicio M.C. Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta 2011, 699:134-152.
125. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., et al. The miqe guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
126. Bustin S.A. Why the need for qPCR publication guidelines? The case for MIQE. Methods 2010, 50:217-226.
127. Radom-Aizik S., Zaldivar F., Oliver S., Galassetti P., Cooper D.M. Evidence for microRNA involvement in exercise-associated neutrophil gene expression changes. J Appl Physiol 2010, 109:252-261.
128. ElSharawy A., Keller A., Flachsbart F., Wendschlag A., Jacobs G., Kefer N., et al. Genome-wide miRNA signatures of human longevity. Aging Cell 2012, 11:607-616.
129. Shen J., Todd N.W., Zhang H., Yu L., Lingxiao X., Mei Y., et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011, 91:579-587.
130. Wei J., Gao W., Zhu C.J., Liu Y.Q., Mei Z., Cheng T., et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011, 30:407-414.
131. Foss K.M., Sima C., Ugolini D., Neri M., Allen K.E., Weiss G.J. Mir-1254 and mir-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011, 6:482-488.
132. Zheng D., Haddadin S., Wang Y., Gu L.Q., Perry M.C., Freter C.E., et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011, 4:575-586.
133. Shen J., Liu Z., Todd N.W., Zhang H., Liao J., Yu L., et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011, 11:374.
134. Weber D.G., Johnen G., Bryk O., Jockel K.H., Bruning T. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma-a pilot study. PLoS One 2012, 7:e30221.
135. Hu Z., Dong J., Wang L.E., Ma H., Liu J., Zhao Y., et al. Serum microRNA profiling and breast cancer risk: the use of mir-484/191 as endogenous controls. Carcinogenesis 2012, 33:828-834.
136. Schwarzenbach H., Milde-Langosch K., Steinbach B., Muller V., Pantel K. Diagnostic potential of PTEN-targeting mir-214 in the blood of breast cancer patients. Breast Cancer Res Treat 2012, 3:933-941.
137. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., Hoon D.S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011, 57:84-91.
138. Wulfken L.M., Moritz R., Ohlmann C., Holdenrieder S., Jung V., Becker F., et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum mir-1233 levels. PLoS One 2011, 6:e25787.
139. Mahn R., Heukamp L.C., Rogenhofer S., von Ruecker A., Muller S.C., Ellinger J. Circulating microRNAs (mirna) in serum of patients with prostate cancer. Urology 2011, 77:1265. [e9-16].
140. Hausler S.F., Keller A., Chandran P.A., Ziegler K., Zipp K., Heuer S., et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010, 103:693-700.
141. Liu A.M., Yao T.J., Wang W., Wong K.F., Lee N.P., Fan S.T., et al. Circulating mir-15b and mir-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012, 2:e000825.
142. Qi P., Cheng S.Q., Wang H., Li N., Chen Y.F., Gao C.F. Serum microRNAs as biomarkers for hepatocellular carcinoma in chinese patients with chronic hepatitis b virus infection. PLoS One 2011, 6:e28486.
143. Zhou H., Guo J.M., Lou Y.R., Zhang X.J., Zhong F.D., Jiang Z., et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med (Berl) 2010, 88:709-717.
144. Liu J., Gao J., Du Y., Li Z., Ren Y., Gu J., et al. Combination of plasma microRNAs with serum ca19-9 for early detection of pancreatic cancer. Int J Cancer 2012, 131:683-691.
145. Morimura R., Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Nagata H., et al. Novel diagnostic value of circulating mir-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011, 105:1733-1740.
146. Li A., Omura N., Hong S.M., Vincent A., Walter K., Griffith M., et al. Pancreatic cancers epigenetically silence sip1 and hypomethylate and overexpress mir-200a/200b in association with elevated circulating mir-200a and mir-200b levels. Cancer Res 2010, 70:5226-5237.
147. Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J.L., et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009, 2:807-813.
148. Wang L.G., Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 2012, 36:e61-e67.
149. Cheng H., Zhang L., Cogdell D.E., Zheng H., Schetter A.J., Nykter M., et al. Circulating plasma mir-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6:e17745.
150. Pu X.X., Huang G.L., Guo H.Q., Guo C.C., Li H., Ye S., et al. Circulating mir-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010, 25:1674-1680.
151. Fang C., Zhu D.X., Dong H.J., Zhou Z.J., Wang Y.H., Liu L., et al. Serum microRNAs are promising novel biomarkers for diffuse large b cell lymphoma. Ann Hematol 2012, 91:553-559.
152. Miyachi M., Tsuchiya K., Yoshida H., Yagyu S., Kikuchi K., Misawa A., et al. Circulating muscle-specific microRNA, mir-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun 2010, 400:89-93.
153. Yu S., Liu Y., Wang J., Guo Z., Zhang Q., Yu F., et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2012, 97:2084-2092.
154. Tijsen A.J., Creemers E.E., Moerland P.D., de Windt L.J., van der Wal A.C., Kok W.E., et al. Mir423-5p as a circulating biomarker for heart failure. Circ Res 2010, 106:1035-1039.
155. Goren Y., Kushnir M., Zafrir B., Tabak S., Lewis B.S., Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012, 14:147-154.
156. Wang G.K., Zhu J.Q., Zhang J.T., Li Q., Li Y., He J., et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010, 31:659-666.
157. Corsten M.F., Dennert R., Jochems S., Kuznetsova T., Devaux Y., Hofstra L., et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010, 3:499-506.
158. Meder B., Keller A., Vogel B., Haas J., Sedaghat-Hamedani F., Kayvanpour E., et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011, 106:13-23.
159. Wang R., Li N., Zhang Y., Ran Y., Pu J. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. Intern Med 2011, 50:1789-1795.
160. Zeng L., Liu J., Wang Y., Wang L., Weng S., Tang Y., et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed) 2011, 3:1265-1272.
161. Redell J.B., Moore A.N., Ward N.H., Hergenroeder G.W., Dash P.K. Human traumatic brain injury alters plasma microRNA levels. J Neurotrauma 2010, 27:2147-2156.
162. Bihrer V., Waidmann O., Friedrich-Rust M., Forestier N., Susser S., Haupenthal J., et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011, 6:e26971.
163. Cui L., Qi Y., Li H., Ge Y., Zhao K., Qi X., et al. Serum microRNA expression profile distinguishes enterovirus 71 and coxsackievirus 16 infections in patients with hand-foot-and-mouth disease. PLoS One 2011, 6:e27071.
164. Wang J.F., Yu M.L., Yu G., Bian J.J., Deng X.M., Wan X.J., et al. Serum mir-146a and mir-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 2010, 394:184-188.